University of Tasmania
Browse

File(s) under permanent embargo

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction

journal contribution
posted on 2023-05-19, 21:14 authored by Kehinde ObamiroKehinde Obamiro, Kunle, R
Patients receiving therapy for the secondary prevention of myocardial infarction (MI) are still at high risk of a major cardiovascular event or death despite the use of currently available treatment strategy. Vorapaxar, an oral protease-activated receptor antagonist, is a novel antiplatelet drug that has been recently approved to provide further risk reduction. The results of two Phase III trials (thrombin receptor antagonists for clinical event reduction and the TRA 2°P-TIMI 50) have showed that vorapaxar, in addition to standard of care therapy, has the potential to provide further risk reduction in patients with prior MI. A search was made on PubMed on articles related to clinical trials and clinical consideration with the use of vorapaxar. This review article summarizes the results of Phase II trials, Phase III trials, subgroup analysis, precautions, and drug interaction with the use of vorapaxar.

History

Publication title

Journal of pharmacy & bioallied sciences

Volume

8

Pagination

98-105

ISSN

0976-4879

Department/School

Tasmanian School of Medicine

Publisher

Medknow Publications

Place of publication

India

Rights statement

© Journal of Pharmacy And Bioallied Sciences

Repository Status

  • Restricted

Socio-economic Objectives

Clinical health not elsewhere classified

Usage metrics

    University Of Tasmania

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC